Bad Blood: CSL Will Challenge FTC Lawsuit Over Its Acquisition of Talecris
Executive Summary
Expressing frustration with regulators, CSL will challenge a Federal Trade Commission lawsuit being filed to block its planned $3.1 billion acquisition of Talecris Biotherapeutics, company executives said May 28
You may also be interested in...
Spilled Blood: CSL & Talecris Terminate Their Merger Deal In Face of FTC Lawsuit
The companies decide it is not worth the cost and time to battle the FTC in court; the derailed deal may signal tougher times for pharma mergers.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011